151910 — SBW Life Sciences Co Income Statement
0.000.00%
Last trade - 00:00
TechnologyHighly SpeculativeSmall Cap
- KR₩122bn
- KR₩132bn
- KR₩48bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 52,623 | 56,967 | 51,482 | 50,852 | 48,310 |
Cost of Revenue | |||||
Gross Profit | -3,726 | 6,239 | 4,125 | 9,612 | 5,710 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 70,513 | 56,372 | 69,098 | 52,383 | 53,259 |
Operating Profit | -17,890 | 595 | -17,616 | -1,531 | -4,948 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16,288 | -1,769 | -27,210 | -15,912 | -7,849 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16,288 | -1,769 | -27,547 | -15,912 | -7,664 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -16,288 | -1,769 | -27,546 | -15,911 | -7,664 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -16,288 | -1,769 | -27,546 | -15,911 | -7,664 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -119 | -14.8 | -120 | -67.4 | -35.7 |
Dividends per Share |